Biocryst Pharmaceuticals (BCRX) Current Leases (2017 - 2026)

Biocryst Pharmaceuticals has reported Current Leases for 10 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 31.2% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 31.2% YoY), and the FY2025 full-year result was $317000.0, down 82.72% from the prior year.
• Current Leases for Q1 2026 stood at $1.2 million, up from $317000.0 in the prior quarter.
• The five-year high for Current Leases was $2.5 million in Q2 2023, with the low at $317000.0 in Q4 2025.
• Historically, Current Leases has averaged $1.7 million across 5 years, with a median of $1.7 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases jumped 117.53% — and 2025, when it tumbled 82.72%.
• Biocryst Pharmaceuticals' Current Leases stood at $1.5 million in 2022, then grew by 4.88% to $1.6 million in 2023, then increased by 15.41% to $1.8 million in 2024, then plunged by 82.72% to $317000.0 in 2025, then jumped by 289.59% to $1.2 million in 2026.
• The last three Current Leases figures came in at $1.2 million (Q1 2026), $317000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.